Subscribe
jarun-ontakrai
Jarun Ontakrai/ Shutterstock.com
14 May 2020Big Pharma

Natera and Illumina settle litigation, agree mutual licence

Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More on this story

Big Pharma
Natera accuses CareDx of infringing DNA testing patents
17 May 2022   Natera has accused rival medical company CareDx of infringing two patents covering its “cell-free” DNA testing technology, Prospera.
Big Pharma
Invitae claims Natera infringed DNA patents
13 May 2021   Generics manufacturer Invitae has filed a lawsuit against rival company Natera claiming that its cancer detection test infringes one of Invitae’s DNA sequencing patents.
Americas
Illumina to acquire Jeff Bezos-backed cancer testing company
23 September 2020   Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?